Rezolute (NASDAQ:RZLT) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Rezolute (NASDAQ:RZLT) from a strong sell rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a report on Tuesday, April 21st. Wedbush upgraded shares of Rezolute from a “neutral” rating to an “outperform” rating and raised their price target for the company from $2.00 to $5.00 in a report on Wednesday, March 25th. Finally, Maxim Group raised their price target on shares of Rezolute from $4.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.75.

Rezolute Stock Performance

NASDAQ RZLT opened at $3.34 on Friday. The company has a market capitalization of $321.61 million, a price-to-earnings ratio of -4.07 and a beta of 0.66. The company’s 50-day simple moving average is $3.14 and its two-hundred day simple moving average is $4.54. Rezolute has a one year low of $1.07 and a one year high of $11.46.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Equities analysts expect that Rezolute will post -0.72 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new stake in Rezolute in the 2nd quarter worth approximately $25,000. Russell Investments Group Ltd. acquired a new stake in Rezolute in the 3rd quarter worth approximately $61,000. Legal & General Group Plc acquired a new stake in Rezolute in the 2nd quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in Rezolute in the 3rd quarter worth approximately $94,000. Finally, Raymond James Financial Inc. acquired a new stake in Rezolute in the 2nd quarter worth approximately $46,000. 82.97% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Rezolute

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: HC Wainwright raised its Q1 2027 EPS estimate, indicating a somewhat better outlook for that quarter. Rezolute analyst estimate update
• Positive Sentiment: The firm also increased its Q2 2027 EPS estimate, another modest improvement in the near-term earnings view. Rezolute analyst estimate update
• Positive Sentiment: HC Wainwright lifted its FY2027 EPS forecast, implying better expected profitability over the medium term. Rezolute analyst estimate update
• Neutral Sentiment: The analyst also updated FY2028 and FY2029/FY2030 estimates, reflecting a broader refresh of the company’s longer-term model. Rezolute analyst estimate update
• Negative Sentiment: HC Wainwright cut its Q4 2026 EPS estimate, signaling weaker expected results in the next reported period. Rezolute analyst estimate update
• Negative Sentiment: The firm lowered its Q3 2027 and Q4 2027 EPS estimates, which may have contributed to the stock moving lower. Rezolute analyst estimate update
• Negative Sentiment: HC Wainwright also reduced its FY2026, FY2028, FY2029, and FY2030 EPS forecasts, pointing to slower anticipated earnings improvement over time. Rezolute analyst estimate update

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.